NUVB – nuvation bio inc. class a (US:NASDAQ)

News

Nuvation Bio (NYSE:NUVB) had its price target raised by analysts at HC Wainwright from $10.00 to $18.00. They now have a "buy" rating on the stock.
Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List
Nuvation Bio (NUVB) Bounces Back 12% on Impressive Clinical Trial Result [Yahoo! Finance]
Lenz Therapeutics: A Close Look [Seeking Alpha]
Nuvation Bio Inc. (NUVB) Presents at Citi Annual Global Healthcare Conference 2025 Transcript [Seeking Alpha]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com